Samsung Bioepis President Go Han-seung Retained

Published 09 Dec.2020 11:42(KST)

[Asia Economy Reporter Cho Hyun-ui] Koh Han-seung, CEO and President of Samsung Bioepis, the bio affiliate of Samsung Group, has been reappointed.

Samsung Bioepis announced on the 9th that it conducted a regular executive personnel reshuffle. It was confirmed that President Koh, whose term ends in March next year, will be reappointed. Koh, who took office as CEO at the founding of Samsung Bioepis in 2012, will challenge to become the longest-serving CEO in Samsung Group since Kim Tae-han, former CEO of Samsung Biologics, after 2010.

President Koh holds a Ph.D. in Genetic Engineering from Northwestern University in the United States. After working at a bio venture company, he joined the Comprehensive Technology Institute in 2000, leading bio development as head of the Bio Health Lab, and has been serving as CEO of Samsung Bioepis since 2012. Industry insiders evaluate that President Koh has once again been recognized for leading the growth of Samsung Bioepis. Samsung Bioepis entered Brazil, the largest pharmaceutical market in Latin America, this year following Europe and the United States. The company plans to expand its business not only in biosimilars but also in new drugs.

Meanwhile, Samsung Biologics announced the day before that it has appointed Vice President John Rim as CEO and President. The industry is paying attention to Samsung Group placing experts from global bio companies as heads of both bio affiliates. The new President Rim holds a master's degree in Chemical Engineering from Stanford University and an MBA from Northwestern University, and has worked at multinational pharmaceutical companies such as Roche and Genentech. This is interpreted as an intention to pursue continuous growth through stability and innovation strategies by leveraging experts with extensive global market experience.